 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 for "Gerd Zettlmeissl"
|
| Ordered by |
|
|
-
Intercell: IOMAI Acquisition granted clearance by US Authorities
(15 Jul 2008)
component of the transaction. Gerd Zettlmeissl, CEO of Intercell, said...
-
Intercell receives milestone payment triggered by initiation of further clinical trial for Flu vaccine with IC31
(16 Jun 2008)
Further clinical trial for a seasonal flu vaccine containing Intercell's adjuvant IC31 being initiated
responses against the three included influenza strains. Gerd Zettlmeissl, CEO...
-
Intercell AG to acquire Iomai Corporation to expand late stage product pipeline and strengthen leadership in vaccine innovation
(14 May 2008)
, Europe and Australia in 2008. Commenting on the transaction, Gerd Zettlmeissl...
-
Intercell completes Phase I clinical trial for an improved seasonal Influenza vaccine formulated with IC31
(29 Feb 2008)
Intercell's strategic Flu partner Novartis to include IC31® in further clinical trials
® in combination with seasonal influenza antigens in humans, states Gerd Zettlmeissl, Chief...
-
Vaccine formulated with Intercells adjuvant IC31 part of a broader collaboration to fight Tuberculosis
(18 Feb 2008)
tuberculosis vaccine program comments Intercells Chief Executive Officer Gerd Zettlmeissl. The preclinical and the Phase I clinical studies performed so far have...
-
Intercell Receives Manufacturer's Licence for Future Commercial Manufacturing of its Vaccine Against Japanese Encephalitis
(18 Jan 2008)
Intercell receives Manufacturer's Licence for its site in Livingston, Scotland
a sufficient launch stock for product approvals in the respective locations, states Gerd Zettlmeissl, Intercell´s Chief Executive Officer. Intercell expects...
-
Staphylococcus aureus vaccine development on track safe and immunogenic in Phase I clinical trials
(22 May 2007)
clinical development ", states Gerd Zettlmeissl, CEO of Intercell. "These data...
|
|
|
|
|
Top